Medtronic Invests Up to $80M in Pi-Cardia to Advance Complex TAVR Technology

Medtronic plc (NYSE: MDT), a global healthcare technology company, announced on September 1, 2026 a strategic investment in Pi-Cardia Ltd., a company focused on leaflet modification technologies for structural heart disease. The move aims to address the needs of increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, giving Medtronic an option to strengthen its structural heart portfolio.

Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the company's ShortCut device in 2027. The deal also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones, for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus potential earn-out payments after any acquisition.

Pi-Cardia's ShortCut is described as the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. In FDA-reviewed clinical studies, the device demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile, according to the companies.

The transactions are subject to regulatory approval and customary closing conditions. Erez Golan, Chief Executive Officer of Pi-Cardia, said Medtronic is "the right partner" to help make leaflet modification a standard part of complex TAVR, citing its global reach. As with any deal contingent on approvals and milestones, outcomes are not guaranteed, and past results do not guarantee future performance.